Anti-Ro52 antibodies in idiopathic inflammatory myopathies: clinical significance across myositis-specific antibody-defined subgroups.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42647225.
- Also identified by DOI 10.1093/rheumatology/keag462.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To investigate the frequency, clinical characteristics, and prognostic value of anti-Ro52 antibodies in patients with idiopathic inflammatory myopathies (IIMs), especially in IIM subgroups with distinct myositis-specific antibodies (MSAs). This cohort included 2,126 patients with IIMs treated at the China-Japan Friendship Hospital between April 2002 and April 2023. Associations between clinical features and outcomes with anti-Ro52 antibodies were evaluated in each MSA-defined subgroup. In total, 978 (46.0%) patients presented with anti-Ro52 antibody positivity. Anti-Ro52 antibodies represented the most common myositis-associated antibody in IIM patients, with notably higher frequencies observed in patients with anti-MDA5+ dermatomyositis (DM) and anti-synthetase syndrome (ASyS) compared to other IIM serotypes. In patients with anti-MDA5+ DM, anti-Ro52 antibodies were associated with interstitial lung disease (ILD), rapidly progressive ILD, and worse prognosis. Coexistence of anti-Ro52 and anti-SSA antibodies was further associated with a worse prognosis in anti-MDA5+ DM. In ASyS, anti-Ro52 antibodies were associated with pulmonary involvement but not with prognosis. In other MSA-defined subgroups, the clinical significance of anti-Ro52 antibodies was limited. Anti-Ro52 antibodies are highly prevalent in patients with IIMs, especially those with anti-MDA5+ DM and ASyS. Anti-Ro52 antibody testing may be a valuable tool for risk stratification and prognostic assessment in anti-MDA5+ DM and ASyS.